Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer.

MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. Cancer (2016) 0.75

Global cancer statistics. CA Cancer J Clin (2011) 185.92

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med (1991) 19.46

Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30

Primary liver cancer: worldwide incidence and trends. Gastroenterology (2004) 11.21

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res (2007) 5.63

Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov (2008) 4.76

Epidemiology of primary liver cancer. Semin Liver Dis (1999) 4.48

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol (2012) 3.88

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04

Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res (2013) 2.61

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther (2010) 2.18

Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol (2011) 2.14

Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A (2003) 1.90

The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene (2004) 1.78

MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol (2012) 1.71

A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res (2007) 1.59

Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology (2009) 1.56

Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res (2013) 1.52

Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer (2006) 1.48

Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol (2010) 1.42

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther (2006) 1.32

mTOR, cancer and transplantation. Am J Transplant (2008) 1.24

Expression of the c-met protooncogene in human hepatocellular carcinoma. Hepatology (1994) 1.21

Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: a retrospective study. J Gastrointest Surg (2007) 1.16

Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res (1997) 1.16

Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. Semin Oncol (2012) 1.15

Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology (1997) 1.14

Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. Cancer Treat Rev (2006) 1.10

Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol (2012) 1.01

Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis. Int J Oncol (2007) 1.01

Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology (2008) 1.00

GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. ACS Chem Biol (2013) 0.97

Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth. Biosci Trends (2011) 0.94

Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. Angiogenesis (2011) 0.93

Expression of hepatocyte growth factor (HGF) and HGF receptor (c-met) proteins in liver diseases: an immunohistochemical study. Liver (1999) 0.93

Liver hepatocyte growth factor does not always correlate with hepatocellular proliferation in human liver lesions: its specific receptor c-met does. Hepatology (1996) 0.91

Targeting MET: why, where and how? Curr Opin Pharmacol (2013) 0.91

Expression of HGF, its receptor c-met, c-myc, and albumin in cirrhotic and neoplastic human liver tissue. J Histochem Cytochem (1997) 0.88

Early development of sunitinib in hepatocellular carcinoma. Expert Rev Anticancer Ther (2009) 0.84

Interplay between receptor tyrosine kinases and hypoxia signaling in cancer. Int J Biochem Cell Biol (2015) 0.81

Off-target effects of c-MET inhibitors on thyroid cancer cells. Mol Cancer Ther (2013) 0.81

[Comparative genomic classification of human hepatocellular carcinoma]. Magy Onkol (2009) 0.79

Detection of disseminated tumour cells in the liver of colorectal cancer patients. Eur J Surg Oncol (2005) 0.76

KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells. Mol Oncol (2015) 0.78